Renal Clearable Chiral Manganese Oxide Supraparticles for In Vivo Detection of Metalloproteinase‐9 in Early Cancer Diagnosis
Advanced Materials · 2025
DOI: 10.1002/adma.202415656 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2025. Verfasst von Hongyu Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Food Science and Technology, International Joint Research Laboratory for Biointerface and Biodetection, School of Food Scienc…. Hauptthemen laut MEDLINE: Manganese Compounds, Matrix Metalloproteinase 9, Oxides, Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
In this study, polypeptide TGGGPLGVARGKGGC‐induced chiral manganese dioxide supraparticles (MnO 2 SPs) are prepared for sensitive quantification of matrix metalloproteinase‐9 (MMP‐9) in vitro and in vivo. The results show that L ‐type manganese dioxide supraparticles ( L ‐MnO 2 SPs) exhibited twice the affinity for the cancer cell membrane receptor CD47 (cluster of differentiation, integrin‐associated protein) than D ‐type manganese dioxide supraparticles ( D ‐MnO 2 SPs) to accumulate at the tumor site after surface modification of the internalizing arginine‐glycine‐aspartic acid (iRGD) ligand, specifically reacting with the MMP‐9, disassembling into ultrasmall nanoparticles (NPs), and efficiently underwent renal clearance. Furthermore, L ‐MnO 2 facilitates the quantification of MMP‐9 in mouse tumor xenografts, as demonstrated by circular dichroism (CD) and magnetic resonance imaging (MRI) within 2 h. A strong linear relationship is observed between MMP‐9 concentration and both CD and MRI intensity, ranging from 0.01 to 10 ng mL −1 . The corresponding limits of detection (LOD) are 0.0054 ng mL −1 for CD and 0.0062 ng mL −1 for MRI, respectively. hese SPs provide a new approach for exploring chiral advanced biosensors for early diagnosis of cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Food Science and Technology, International Joint Research Laboratory for Biointerface and Biodetection, School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu, 214122, China.
- Department of Instrumentation and Analytical Chemistry, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, Liaoning, 116023, Chi…
- Institute for New Energy Materials and Low Carbon Technologies, School of Materials Science and Engineering, Tianjin University of Technology, Tianjin, 300384, China.
ORCID-Profile: Aihua Qu
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Natural Science Foundation of Jiangsu Province
- National funded postdoctoral researcher program
- National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
Zitieren
APA
Zhang, H., Chen, P., Shi, W., Qu, A., Sun, M., & Kuang, H. (2025). Renal Clearable Chiral Manganese Oxide Supraparticles for In Vivo Detection of Metalloproteinase‐9 in Early Cancer Diagnosis. Advanced Materials. https://doi.org/10.1002/adma.202415656
Vancouver
Zhang H, Chen P, Shi W, Qu A, Sun M, Kuang H. Renal Clearable Chiral Manganese Oxide Supraparticles for In Vivo Detection of Metalloproteinase‐9 in Early Cancer Diagnosis. Advanced Materials. 2025. doi:10.1002/adma.202415656
BibTeX
@article{Zhang2025,
author = {Zhang, Hongyu and Chen, Panpan and Shi, Wenxiong and Qu, Aihua and Sun, Maozhong and Kuang, Hua},
title = {Renal Clearable Chiral Manganese Oxide Supraparticles for In Vivo Detection of Metalloproteinase‐9 in Early Cancer Diagnosis},
journal = {Advanced Materials},
year = {2025},
doi = {10.1002/adma.202415656}
}
EUVIMED